For the biological activity and structure-activity relationships of Tofacitinib {systematic name: 3- [(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d] pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile} derivatives, see: Changelian et al. (2003) ; Flanagan et al. (2010) ; Zerbini & Lomonte (2012) . For details of the synthesis, see: Babu et al. (2010) .
Experimental
Crystal data (Changelian et al. (2003) and Flanagan et al., (2010) ) which has recently been approved by the US Food and Drug Administration for the treament of rheumatoid athritis. Furthermore, it is currently in late stage clinical trials for treatment of psoriasis, inflammatory bowel disease, transplant rejection and other immunological disorders (Zerbini & Lomonte, (2012) ). Searching for novel JAK inhibitors, the title compound was synthesized as a key intermediate possessing the Boc-protected Tofacitinib side chain.
In the crystal structure of the title compound the piperidine ring adopts a slightly distorted chair conformation with a torsion angle between the cis substituents of 43.0 (3)°. The carbamate group shows a dihedral angle of 60.3 (5)° relative to the amide group. The plane defined by atoms C17, C19, C20 and N21 is slightly bent out of the plane of the amide group by 13.3 (2)°.
The title compound was prepared by cyanoacetylation of a precursor possessing a free piperidine NH-function (Babu et al., (2010) ) using dicyclohexylcarbodiimide (DCC) and cyanoacetic acid. carbamate (2.80 g, 12.3 mmol) was dissolved in 25 ml of dry methylen chloride and stirred under argon atmosphere. Cyano acetic acid (0.82 g, 9.64 mmol) and N,N′-dicyclohexylcarbodiimide (1.99 g, 9.64 mmol) was added in one portion while cooling with ice. After 15 min at 273 K, the ice bath was removed, the mixture warmed to room temperature (298 K) and stirring was continued for 3 h. N,N′-dicyclohexylurea was removed by filtration, washed with methylen chloride and the filtrate concentrated under reduced pressure.
tert
Purification by column chromatography (SiO 2 , methylen chloride/ethyl acetate: 7 + 3) yielded the title compound as colorless solid (2.18 g, 84.3%). Crystals of the title compound were obtained by slow evaporation of methanol at room temperature (298 K).
Refinement
Hydrogen atoms attached to carbons were placed at calculated positions with C-H = 0.95 Å (aromatic) or 0.99-1.00 Å (sp 3 C-atom). All H atoms were refined with isotropic displacement parameters (set at 1.2-1.5 times of the U eq of the parent atom). Because no strong anomalous scattering atoms are present Friedel opposites were merged in the refinement.
The absolute configuration was assigned according to the synthesis.
Computing details
Data collection: APEX2 (Bruker, 2006 ); cell refinement: SAINT (Bruker, 2006) ; data reduction: SAINT (Bruker, 2006 (Sheldrick, 2008) ; molecular graphics: PLATON (Spek, 2009) ; software used to prepare material for publication:
PLATON (Spek, 2009 ).
Figure 1
Crystal structure (oder molecular structure) of the title compound with labeling and displacement ellipsoids drawn at the 50% probability level.
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